DOCSLIB.ORG

Scientific Programme Sunday, 12. July 2020 Plenary Session State-Of-The-Art on Hemophilia and Rare Bleeding Disorders State-Of-T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Scientific Programme Sunday, 12. July 2020 Plenary Session State-Of-The-Art on Hemophilia and Rare Bleeding Disorders State-Of-T ISTH 2020 Virtual Congress, July 12, - 14, 2020 Scientific Programme Sunday, 12. July 2020 Plenary Session 08:00 - 08:30 Virtual Meeting Room 1 Plenary Session Advances in Gene Therapy and Ethical Aspects 08:00 Speaker: Luigi Naldini (Italy) State-of-the-Art Session 08:45 - 10:00 Virtual Meeting Room 1 State-of-the-Art on Hemophilia and Rare Bleeding Disorders Progress and Obstacles to Hemophilia Gene Therapy 08:45 Speaker: Amit Nathwani (United Kingdom) Immunogenicity of Adeno-Associated Vectors 09:10 Speaker: Federico Mingozzi (United States) Immune Responses to Factor VIII in Hemophilia 09:35 Speaker: Sebastien Lacroix-Desmazes (France) State-of-the-Art Session 08:45 - 10:00 Virtual Meeting Room 2 State-of-the-Art on Thrombotic Microangiopathies Differential Diagnosis of Thrombotic Microangiopathies 08:45 Speaker: Giuseppe Remuzzi (Italy) First Guideline of ISTH on Diagnosis and Treatment of Thrombotic 09:10 Thrombocytopenic Purpura Speaker: X. Long Zheng (United States) Drug-Associated Thrombotic Microangiopathies: Emerging Toxicities of 09:35 Novel Drugs Speaker: Marcel Levi (United Kingdom) State-of-the-Art Session 08:45 - 10:00 Virtual Meeting Room 3 State-of-the-Art on Fibrinolysis and Proteolysis Visualizing Thrombosis to Improve Thrombolysis 08:45 Speaker: John W. Weisel (United States) Page 1 / 116 ISTH 2020 Virtual Congress, July 12, - 14, 2020 Scientific Programme PAI-1 and the Multi-Morbidity of Aging 09:10 Speaker: Douglas E. Vaughan (United States) Fibrinolysis and Bleeding of Unknown Cause 09:35 Speaker: Ingrid Pabinger (Austria) State-of-the-Art Session 08:45 - 10:00 Virtual Meeting Room 4 State-of-the-Art on Role of Hemostatic System in Cancer, Inflammation and Immunity The Role of Platelets in Sepsis 08:45 Speaker: Oonagh Shannon (Sweden) Fibrinolytic Factors in Cancer Progression 09:10 Speaker: Marie Ranson (Australia) Inflammatory Roles of Platelets 09:35 Speaker: John Semple (Sweden) State-of-the-Art Session 08:45 - 10:00 Virtual Meeting Room 5 State-of-the-Art on Arterial Thromboembolism 120 Years of Aspirin: Retiring, Recombining, or Repurposing? 08:45 Speaker: Carlo Patrono (Italy) DOAC for the Treatment of Arterial Thrombosis 09:10 Speaker: Sonia S. Anand (Canada) Triple or Double Therapy for Patients with Atrial Fibrillation and Acute 09:35 Coronary Syndrome/Percutaneous Coronary Intervention? With What Drugs? Speaker: Renato Lopes (United States) State-of-the-Art Session 08:45 - 10:00 Virtual Meeting Room 6 State-of-the-Art on Platelets and Megakaryocytes Inherited Thrombocytopenias as a Model to Study the Mechanisms of 08:45 Platelet Formation Speaker: Hana Raslova (France) Small GTPases in Megakaryocyte and Platelet Biology 09:10 Speaker: Wolfgang Bergmeier (United States) Gpibα- Drive Force for Liver Thrombopoietin Generation 09:35 Speaker: Heyu Ni (Canada) Page 2 / 116 ISTH 2020 Virtual Congress, July 12, - 14, 2020 Scientific Programme Oral Communication Session 10:15 - 11:30 Virtual Meeting Room 1 Arterial Thromboembolism Oral Communication Session Q&A 11:15 Oral Communication Session 10:15 - 11:30 Virtual Meeting Room 2 Fibrinolysis and Proteolysis Oral Communication Session Q&A 11:15 Oral Communication Session 10:15 - 11:30 Virtual Meeting Room 3 Hemophilia and Rare Bleeding Disorders Oral Communication Session 1 Q&A 11:15 Oral Communication Session 10:15 - 11:30 Virtual Meeting Room 4 Platelets and Megakaryocytes Oral Communication Session Q&A 11:15 Oral Communication Session 11:45 - 13:00 Virtual Meeting Room 1 Coagulation and Natural Anticoagulants Oral Communication Session Q&A 12:45 Oral Communication Session 11:45 - 13:00 Virtual Meeting Room 2 Role of Hemostatic System in Cancer, Inflammation and Immunity Oral Communication Session Q&A 12:45 Page 3 / 116 ISTH 2020 Virtual Congress, July 12, - 14, 2020 Scientific Programme Oral Communication Session 11:45 - 13:00 Virtual Meeting Room 3 Thrombotic Microangiopathies Oral Communication Session Q&A 12:45 Oral Communication Session 11:45 - 13:00 Virtual Meeting Room 4 COVID-19 Oral Communication Session Q&A 11:45 Plenary Session 13:15 - 13:45 Virtual Meeting Room 1 Plenary Session VWF in Hemostasis: From Basic Science to Clinic 13:15 Speaker: Peter J. Lenting (France) On-Demand Poster Session 14:00 - 15:00 Virtual Meeting Room 6 Arterial Thromboembolism Abstracts The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020. Acute Coronary Syndromes Clopidogrel Resistance and P2y12 Receptor Gene Polymorphisms in Patients with Non-ST Elevated Acute Coronary Syndrome Improved Antithrombotic Activity and Diminished Bleeding Side Effect of a PEGylated αIIbβ3 Antagonist, Disintegrin Correlation of D-Dimer Levels with Troponin I in Patients with Acute Myocardial Infarction How Much Evidence Is Needed to Conclude against the Use of Oxygen Therapy in Acute Myocardial Infarction? White Clot is More Permeable and Stronger than the Red Clot Thrombophilia and Myocardial Infarction with Non-Obstructive Coronary Arteries Contribution of Fibrin and von Willebrand Factor to Platelet Adhesion on Ruptured Atherosclerotic Plaque in Acute Myocardial Infarction A Case Report of a Patient with Hereditary Angioedema and Samter´s Syndrome Treated with Anticoagulant of Direct Action Anti Xa (Rivaroxaban), Secondary to Angioplasty due to Ischemic Heart Disease Page 4 / 116 ISTH 2020 Virtual Congress, July 12, - 14, 2020 Scientific Programme Differential Effects of Clopidogrel with or without Aspirin on Platelet Reactivity and Coagulation Activation: A randomized placebo-controlled trial in healthy volunteers Hydrodynamic activation of von Willebrand factor under flow conditions may contribute to thrombotic complications in coronary heart disease Antiphospholipid antibodies in Acute Myocardial Infarction BDNFVal66Met Polymorphism Affects Cardiac Remodeling and Modulates Macrophage Polarization After Myocardial Infarction Plasma Exosomes in Patients with ST‐Elevation Acute Myocardial Infarction (STEMI) and in Patients with Stable Coronary Artery Disease (CAD) Interventions needed in antithrombotic therapy in a real life hospitalized population; Evaluation of interventions initiated by a multidisciplinary antithrombotic team regarding antithrombotic agent combinations in in-patient care Changes of soluble fibrin-monomer complex concentration in different types of coronary artery disease In-vivo Biomarkers of Platelet Function in Women with Ischemic Heart Disease: What We Learned from the EVA Study Clot formation, ultrastructure and lysis in patients with acute phase myocardial infarction Myocardial infarction as a first symptom of activated protein C resistance associated to hyperhomocyteinemia Postoperative Dual Antiplatelet Therapy is Influenced by Platelet Regeneration New Rat Model of Ferric Chloride-induced Acute Coronary Artery Thrombosis for Pharmaceutical Treatment of Myocardial Infarction Smoking Status as Risk Factor and Risk Factors in Young and Elderly Patients Suffered from Myocardial Infarction Atherosclerosis High-Dose Atorvastatin – Loaded Microbubbles-Mediated Sonoporation Therapy using B - Mode Ultrasound - Guided Focused Electrohydraulic Shock Waves Decreases Inflammation and Restenosis after Laser Angioplasty of Advanced Atherosclerotic Severe Stenosis Synthetic Antisense Oligodeoxynucleotides - Loaded Microbubbles - Mediated Transfection Therapy using B-Mode Ultrasound - Guided Focused Shock Waves Decreases Neointimal Hyperplasia Restenosis after Laser Angioplasty of Advanced Atherosclerotic Severe Stenosis Effect of Phosphomimetic Endothelial Nitric Oxide Synthase - Loaded Microbubbles- Mediated Transfection Therapy using B-Mode Ultrasound-Guided Focused - Low Level Confocal Dual-Pulse Electrohydraulic Shock Waves on Early Stage Atherosclerosis Intravenous Lipid-Based Encapsulated Paclitaxel Nanoparticles Administration Enhances 5-Aminolevulinic Acid- Mediated B- Mode Ultrasound- Guided Focused- Electrohydraulic Shock Wave Sonodynamic Therapy of Intermediated Stage Atherosclerosis Immuno-Radio-Metric TSH in TRH Test of Optimal Substitutive Thyroid Hormones Association of MMP-12 and SDF1 with Symptomatic and Asymptomatic Atherosclerosis Antioxidant defense gene polymorphism in the Nenets population Diabetes mellitus and risk of intracranial atherosclerosis: A meta-analysis using real-world evidence Page 5 / 116 ISTH 2020 Virtual Congress, July 12, - 14, 2020 Scientific Programme In vitro occlusive clot growth and retraction Selective targeting of shear gradient activated von Willebrand Factor by the novel single- chain antibody scFv-A1 reduces occlusive thrombus formation Trash feet : is anticoagulation therapy useful? Impact of gut microbiota on late atherosclerosis and atherothrombosis: a study with germ- free mice In vitro investigation of the Impact of BCR-ABL Tyrosine Kinase Inhibitors on endothelial cells In vitro Evaluation of the Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture Evaluation of the selectivity of BCR-ABL tyrosine kinase inhibitors (TKIs): a systematic review The role of ERp44 in the atherosclerosis Importance of arginase-1 in erythrocytes for smooth muscle cell calcification and atherosclerosis Absence of Protein Tyrosine Phosphatase-1B in Smooth Muscle Cells Promotes Perivascular Fibrosis: Role of Receptor Tyrosine Kinase Signaling Relationship between distal venous thrombosis and asymptomatic atherosclerotic disease Un Untargeted Lipidomic Analysis Reveals Lactosylceramide
Load more

Recommended publications
  • Guideline on Clinical Investigation of Recombinant and Human Plasma-Derived 9 Factor IX Products’ (EMA/CHMP/BPWP/144552/2009 Rev
    1 15 November 2018 2 EMA/CHMP/BPWP/144552/2009 rev. 2 Corr. 1 3 Committee for medicinal products for human use (CHMP) 4 Guideline on clinical investigation of recombinant and 5 human plasma-derived factor IX products 6 Draft Draft Agreed by Blood Products Working Party (BPWP) August 2018 Adopted by Committee for Medicinal Products for Human Use (CHMP) 15 November 2018 Start of public consultation 3 December 2018 End of public consultation 30 June 2019 7 8 This guideline replaces ‘Guideline on clinical investigation of recombinant and human plasma-derived 9 factor IX products’ (EMA/CHMP/BPWP/144552/2009 Rev. 1, Corr. 1) 10 Comments should be provided using this template. The completed comments form should be sent to [email protected] 11 Keywords Recombinant factor IX, plasma-derived factor IX, efficacy, safety, immunogenicity, inhibitor, thrombogenicity, anaphylactic reactions, potency assays 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. 12 Guideline on the clinical investigation of recombinant and 13 human plasma-derived factor IX products 14 Table of contents 15 Executive summary ..................................................................................... 4 16 1. Introduction (background) .....................................................................
    [Show full text]
  • MONONINE (“Difficulty ® Monoclonal Antibody Purified in Concentrating”; Subject Recovered)
    CSL Behring IU/kg (n=38), 0.98 ± 0.45 K at doses >95-115 IU/kg (n=21), 0.70 ± 0.38 K at doses >115-135 IU/kg (n=2), 0.67 K at doses >135-155 IU/kg (n=1), and 0.73 ± 0.34 K at doses >155 IU/kg (n=5). Among the 36 subjects who received these high doses, only one (2.8%) Coagulation Factor IX (Human) reported an adverse experience with a possible relationship to MONONINE (“difficulty ® Monoclonal Antibody Purified in concentrating”; subject recovered). In no subjects were thrombo genic complications MONONINE observed or reported.4 only The manufacturing procedure for MONONINE includes multiple processing steps that DESCRIPTION have been designed to reduce the risk of virus transmission. Validation studies of the Coagulation Factor IX (Human), MONONINE® is a sterile, stable, lyophilized concentrate monoclonal antibody (MAb) immunoaffinity chromatography/chemical treatment step and of Factor IX prepared from pooled human plasma and is intended for use in therapy nanofiltration step used in the production of MONONINE doc ument the virus reduction of Factor IX deficiency, known as Hemophilia B or Christmas disease. MONONINE is capacity of the processes employed. These studies were conducted using the rel evant purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of enveloped and non-enveloped viruses. The results of these virus validation studies utilizing immunoaffinity chromatography. A murine monoclonal antibody to Factor IX is used as an a wide range of viruses with different physicochemical properties are summarized in Table affinity ligand to isolate Factor IX from the source material.
    [Show full text]
  • High Prevalence of Sticky Platelet Syndrome in Patients with Infertility and Pregnancy Loss
    Journal of Clinical Medicine Article High Prevalence of Sticky Platelet Syndrome in Patients with Infertility and Pregnancy Loss Eray Yagmur 1,* , Eva Bast 2, Anja Susanne Mühlfeld 3, Alexander Koch 4, Ralf Weiskirchen 5 , Frank Tacke 6 and Joseph Neulen 7 1 Medical Care Center, Dr. Stein and Colleagues, D-41169 Mönchengladbach, Germany 2 Department of Gynecology and Obstetrics, Bürgerhospital Frankfurt, D-60318 Frankfurt, Germany 3 Division of Nephrology and Clinical Immunology,RWTH-University Hospital Aachen, D-52074 Aachen, Germany 4 Department of Medicine III, RWTH-University Hospital Aachen, D-52074 Aachen, Germany 5 Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry, RWTH-University Hospital Aachen, D-52074 Aachen, Germany 6 Department of Hepatology and Gastroenterology,Charité University Medical Center, D-10117 Berlin, Germany 7 Department of Gynecological Endocrinology and Reproductive Medicine, RWTH-University Hospital Aachen, D-52074 Aachen, Germany * Correspondence: [email protected]; Tel.: +49-2161-8194-442 Received: 26 July 2019; Accepted: 26 August 2019; Published: 28 August 2019 Abstract: Platelet hyperaggregability, known as sticky platelet syndrome (SPS), is a prothrombotic disorder that has been increasingly associated with pregnancy loss. In this retrospective study, we aimed to investigate the clinical and diagnostic relevance of SPS in 208 patients with infertility and unexplained pregnancy loss history. We studied 208 patients that had been referred to undergo a dose-dependent platelet aggregation response to adenosine diphosphate and epinephrine using light transmission aggregometry modified by Mammen during an 11-year period. Patients’ platelet aggregation response was compared with platelet function in 29 female healthy controls of fertile age with no previous history of pregnancy loss.
    [Show full text]
  • The Rare Coagulation Disorders
    Treatment OF HEMOPHILIA April 2006 · No. 39 THE RARE COAGULATION DISORDERS Paula HB Bolton-Maggs Department of Haematology Manchester Royal Infirmary Manchester, United Kingdom Published by the World Federation of Hemophilia (WFH) © World Federation of Hemophilia, 2006 The WFH encourages redistribution of its publications for educational purposes by not-for-profit hemophilia organizations. In order to obtain permission to reprint, redistribute, or translate this publication, please contact the Communications Department at the address below. This publication is accessible from the World Federation of Hemophilia’s web site at www.wfh.org. Additional copies are also available from the WFH at: World Federation of Hemophilia 1425 René Lévesque Boulevard West, Suite 1010 Montréal, Québec H3G 1T7 CANADA Tel. : (514) 875-7944 Fax : (514) 875-8916 E-mail: [email protected] Internet: www.wfh.org The Treatment of Hemophilia series is intended to provide general information on the treatment and management of hemophilia. The World Federation of Hemophilia does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. Dose schedules and other treatment regimes are continually revised and new side effects recognized. WFH makes no representation, express or implied, that drug doses or other treatment recommendations in this publication are correct. For these reasons it is strongly recommended that individuals seek the advice of a medical adviser and/or to consult printed instructions provided by the pharmaceutical company before administering any of the drugs referred to in this monograph. Statements and opinions expressed here do not necessarily represent the opinions, policies, or recommendations of the World Federation of Hemophilia, its Executive Committee, or its staff.
    [Show full text]
  • Clinical Commissioning Policy: Susoctocog Alfa for Treating Bleeding Episodes in People with Acquired Haemophilia a (All Ages)
    Clinical Commissioning Policy: Susoctocog alfa for treating bleeding episodes in people with acquired haemophilia A (all ages) NHS England Reference: 170061P 1 NHS England INFORMATION READER BOX Directorate Medical Operations and Information Specialised Commissioning Nursing Trans. & Corp. Ops. Commissioning Strategy Finance Publications Gateway Reference: 07603 Document Purpose Policy Clinical commissioning policy: Susoctocog alfa for treating bleeding Document Name episodes in people with acquired haemophilia A (all ages) Author Specialised Commissioning Team Publication Date 29 June 2018 Target Audience CCG Clinical Leaders, Care Trust CEs, Foundation Trust CEs , Medical Directors, Directors of PH, Directors of Nursing, NHS England Regional Directors, NHS England Directors of Commissioning Operations, Directors of Finance, NHS Trust CEs Additional Circulation #VALUE! List Description Routinely Commissioned - NHS England will routinely commission this specialised treatment in accordance with the criteria described in this policy. Cross Reference 0 Superseded Docs 0 (if applicable) Action Required 0 Timing / Deadlines By 00 January 1900 (if applicable) Contact Details for [email protected] further information 0 0 0 0 0 0 Document Status This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet. 2 Standard Operating Procedure: Clinical Commissioning Policy: Susoctocog alfa for treating bleeding episodes in people with acquired haemophilia A (all ages) First published: June 2018 Prepared by the National Institute for Health and Care Excellence (NICE) Commissioning Support Programme Published by NHS England, in electronic format only.
    [Show full text]
  • Sticky Platelet Syndrome
    SEMINARS IN THROMBOSIS AND HEMOSTASIS—VOL. 25, NO. 4, 1999 Sticky Platelet Syndrome EBERHARD F. MAMMEN, M.D. ABSTRACT The sticky platelet syndrome (SPS) is an autosomal dominant platelet disorder associated with arterial and venous thromboembolic events. It is characterized by hyperaggregability of platelets in platelet-rich plasma with adenosine diphosphate (ADP) and epinephrine (type I), epinephrine alone (type II), or ADP alone (type III). Clinically, patients may present with angina pectoris, acute myocardial infarc• tion (MI), transient cerebral ischemic attacks, stroke, retinal thrombosis, peripheral arterial thrombosis, and venous thrombosis, frequently recurrent under oral anticoagulant therapy. Clinical symptoms, espe• cially arterial, often present following emotional stress. Combinations of SPS with other congenital throm- bophilic defects have been described. Low-dose aspirin treatment (80 to 100 mg) ameliorates the clinical symptoms and normalizes hyperaggregability. The precise etiology of this defect is at present not known, but receptors on the platelet surface may be involved. Normal levels of platelet factor 4 (PF4) and p-throm- boglobulin in plasma suggest that the platelets are not activated at all times; they appear to become hyper• active upon ADP or adrenaline release. In vivo clumping could temporarily or permanently occlude a ves• sel, leading to the described clinical manifestations. The syndrome appears to be prominent especially in patients with unexplained arterial vascular occlusions. Keywords: Platelets,
    [Show full text]
  • Scientific Program Saturday, 17. July 2021 Factor VIII, Factor IX and Rare
    Scientific programThe XXIX Congress of the International Society on Thrombosis and Haemostasis July 17-21, 2021 Philadelphia, U.S. Saturday, 17. July 2021 SSC Session 08:00 - 10:00 R1 Factor VIII, Factor IX and Rare Coagulation Disorders Introduction 08:00 - 08:02 Speaker: Johnny Mahlangu, ZA Non-Factor Replacement Therapies 08:02 - 08:02 Moderators: Johnny Mahlangu, South Africa, Tarek Owaidah, Saudi Arabia In Patients on Non-Factor Therapies, Exposure to Clotting 08:02 - 08:14 Factor Replacement Should Be Early (Debate) Speaker: Manuel Carcao, CA In Patients on Non-Factor Therapies, Exposure to Clotting 08:14 - 08:26 Factor Replacement Should Be Early (Debate) Speaker: Jayanthi Alamelu, GB Non-Factor Replacement Therapy Versus Factor Replacement 08:26 - 08:38 Therapy Risks -There Is No Free Lunch (Debate) Speaker: Bhavya Doshi, US Non-Factor Replacement Therapy Versus Factor Replacement 08:38 - 08:50 Therapy Risks -There Is No Free Lunch (Debate) Speaker: Gili Kenet, IL Beyond Annualized Bleed Rates What Should Be the Alternative 08:50 - 09:02 Endpoints for Non-Replacement Therapies Speaker: Alok Srivastava, IN Q&A Session 09:02 - 09:06 Gene Therapy 09:06 - 09:06 Moderators: Valder Arruda, United States, Savita Rangarajan, United Kingdom Anti Adeno-Associated Virus Antibodies Antibodies: What Are 09:06 - 09:18 the Standardization Issues? Speaker: David Lillicrap, CA Rationale for Adeno-associated Virus (AAV) Mediated Gene 09:24 - 09:30 Therapy in Patients With Anti Adeno-associated Virus Antibodies Speaker: David Cooper, NL What Should We Be Following-up Post Gene Therapy? 09:30 - 09:42 Speaker: Barbara A.
    [Show full text]
  • Bebulin VH Corifact Factor VII Concentrate
    P RODUCTS TO TREAT RARE FACTOR DEFICIENCIES Product Plasma source Fractionation Viral inactivation Vial size Storage Availability USA: volunteer, Vapour heat @ 60°C for 10 hr at Available through Special Bebulin VH remunerated Ion exchange 190 mbar, then 80°C for 1 hr @ 600 IUs 2‐8°C Access Programme. Manufactured by plasmapheresis adsorption 375 mbar Shire donors distributed in all provinces. Comments Factor IX complex containing factors II, VII, IX and X, heparin added. Product Plasma source Fractionation Viral inactivation Vial size Storage Availability Purification steps: 1) Precipitation/adsorption 250 IUs USA: volunteer, (4 mL of diluent) 2) Ion exchange chromatography Corifact remunerated Multiple Licensed by Health Canada. 1,250 IUs 2‐8°C Manufactured by plasmapheresis precipitation 3) Heat‐treatment (+60°C for 10 (20 mL of diluent) Distributed in all provinces. CSL Behring donors hours in an aqueous solution) 4) Virus filtration over two 20 nm Mix2Vial filters in series Comments Indicated for routine prophylaxis and peri‐operative management of surgical bleeding in patients with congenital factor XIII deficiency. Product Plasma source Fractionation Viral inactivation Vial size Storage Availability Factor VII USA: volunteer, Aluminium Vapour heat @ 60°C for 10 hr at Available through Special remunerated concentrate hydroxide 190 mbar, then 80°C for 1 hr @ 600 IUs 2‐8°C Access Programme. Manufactured by plasmapheresis adsorption 375 mbar Distributed in all provinces. Shire donors Comments Used to treat factor VII deficiency. 1 Product Plasma source Fractionation Viral inactivation Vial size Storage Availability Factor XI USA: volunteer, Affinity heparin Available through Special concentrate remunerated sepharose Dry heat @ 80°C, 72 hr 1,000 IUs 2‐8°C Access Programme.
    [Show full text]
  • Tavalisse™ (Fostamatinib) (Oral) Document Number: IC-0361 Last Review Date: 02/02/2021 Date of Origin: 06/01/2018 Dates Reviewed: 06/2018, 02/2019, 02/2020, 02/2021
    Tavalisse™ (fostamatinib) (Oral) Document Number: IC-0361 Last Review Date: 02/02/2021 Date of Origin: 06/01/2018 Dates Reviewed: 06/2018, 02/2019, 02/2020, 02/2021 I. Length of Authorization Coverage is provided for six months and may be renewed. II. Dosing Limits A. Quantity Limit (max daily dose) [NDC Unit]: 100 mg tablets – 2 tablets per day 150 mg tablets – 2 tablets per day B. Max Units (per dose and over time) [HCPCS Unit]: 300 mg daily III. Initial Approval Criteria 1,2 Coverage is provided in the following conditions: Patient is at least 18 years of age; AND Universal Criteria 1 Patient is not receiving a thrombopoietin receptor agonist or mimetic (e.g., romiplostim, eltrombopag, lusutrombopag, avatrombopag, etc.); AND Laboratory values are current (i.e., drawn within the previous 28 days); AND Fostamatinib is not being used to attempt to normalize platelet count; AND Patient will avoid concomitant therapy with any of the following: o Coadministration with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole, etc.), or if therapy is unavoidable, the patient will be monitored closely for adverse reaction and/or dose modifications will be implemented; AND o Coadministration with strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John’s Wort, etc.); AND Chronic Immune Thrombocytopenia (ITP) † 1-5 Patient has had persistent/chronic ITP for at least 3 months; AND Proprietary & Confidential © 2021 Magellan Health, Inc. Patient has previously failed any of the following treatments for ITP: Patient has failed previous therapy with corticosteroids (i.e., patient had no response to at least a 3-month trial or is corticosteroid-dependent); OR Patient has failed previous therapy with immunoglobulins; OR Patient has had a splenectomy; OR Patient has failed previous therapy with a thrombopoietin receptor agonist; AND The patient is at increased risk for bleeding as indicated by platelet count of less than 30 × 109/L (30,000/mm³) † FDA Approved Indication(s) IV.
    [Show full text]
  • The Use of Total Thrombus Formation Analysis System As a Tool to Assess Platelet Function in Bleeding and Thrombosis Risk—A Systematic Review
    International Journal of Molecular Sciences Review The Use of Total Thrombus Formation Analysis System as a Tool to Assess Platelet Function in Bleeding and Thrombosis Risk—A Systematic Review Joanna Sikora 1,*,† , Aleksandra Karczmarska-Wódzka 1,†, Joanna Bugieda 1 and Przemysław Sobczak 2 1 Research and Education Unit for Experimental Biotechnology, Department of Transplantology and General Surgery, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru´n, 85-094 Bydgoszcz, Poland; [email protected] (A.K.-W.); [email protected] (J.B.) 2 Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru´n, 85-094 Bydgoszcz, Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-52-585-59-76; Fax: +48-52-585-43-80 † These authors contributed equally to this work. Abstract: Background. Today there are many devices that can be used to study blood clotting disorders by identifying abnormalities in blood platelets. The Total Thrombus Formation Analysis System is an automated microchip flow chamber system that is used for the quantitative analysis of clot formation under blood flow conditions. For several years, researchers have been using a tool to analyse various clinical situations of patients to identify the properties and biochemical processes occurring within platelets and their microenvironment. Methods. An investigation of recent published literature was conducted based on PRISMA. This review includes 52 science papers directly related to the use of the Total Clot Formation Analysis System in relation to bleeding, Citation: Sikora, J.; Karczmarska- surgery, platelet function assessment, anticoagulation monitoring, von Willebrand factor and others.
    [Show full text]
  • The Potential Role of Recombinant Activated FVII in the Management of Critical Hemato-Oncological Bleeding: a Systematic Review
    Bone Marrow Transplantation (2007) 39, 729–735 & 2007 Nature Publishing Group All rights reserved 0268-3369/07 $30.00 www.nature.com/bmt REVIEW The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review M Franchini1, D Veneri2 and G Lippi3 1Servizio di Immunoematologia e Trasfusione – Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy; 2Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Universita` di Verona, Verona, Italy and 3Dipartimento di Scienze Biomediche e Morfologiche, Istituto di Chimica e Microscopia Clinica, Universita` di Verona, Verona, Italy Recombinant activated factor VII (rFVIIa) is an hemo- situations unresponsive to conventional therapy to control static agent that was originally developed for the excessive bleeding and reduce exposure to allogeneic blood. treatment of hemorrhage in patients with hemophilia and These include intracerebral hemorrhage, oral anticoagu- inhibitors.However, in the last few years rFVIIa has been lant-induced hemorrhage, thrombocytopenia, bleeding employed with success in a broad spectrum of congenital associated with hepatic failure, major surgery, trauma and acquired bleeding conditions.In this systematic review and life-threatening obstetrical, and gynecologic hemor- we present the current knowledge on the use of this drug in rhagic complications.5–9 patients suffering from hemato-oncological disorders, In this systematic review we have collected the available which are quite commonly complicated by severe hemor- data from the literature on the use of rFVIIa in hemato- rhage.On the whole, data in the literature suggest a oncological patients with severe bleeding, unresponsive to potential role for rFVIIa in the management of bleeding standard therapy.
    [Show full text]
  • Blood Modifier Agents Policy #: Rx.01.208
    Pharmacy Policy Bulletin Title: Blood Modifier Agents Policy #: Rx.01.208 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification, age, quantity, or formulary restrictions (ie limits on non-preferred drugs). Individual member benefits must be verified. This pharmacy policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety, or FDA approval may have changed. This Pharmacy Policy will be regularly updated as scientific and medical literature becomes available. This information may include new FDA-approved indications, withdrawals, or other FDA alerts. This type of information is relevant not only when considering whether this policy should be updated, but also when applying it to current requests for coverage. Members are advised to use participating pharmacies in order to receive the highest level of benefits. Intent: The intent of this policy is to communicate the medical necessity criteria for eltrombopag olamine (Promacta®), fostamatinib disodium (Tavalisse™), avatrombopag (Doptelet®), lusutrombopag (Mulpleta®) as provided under the member's prescription drug benefit. Description: Idiopathic thrombocytopenia purpura (ITP): ITP is an immune disorder in which the blood doesn't clot normally. ITP can cause excessive bruising and bleeding and can be characterized as an unusually low level of platelets, or thrombocytes, in the blood results in ITP. Thrombocytopenia in patients with hepatitis C: Thrombocytopenia can occur in patients with chronic hepatitis C virus (HCV) infection.
    [Show full text]